Probenecid, a medication commonly used to treat gout and gouty arthritis, has been studied for its potential to increase the effectiveness of tigecycline, an antibiotic used to treat various bacterial infections. According to a study published in the Journal of Clinical Pharmacology, probenecid may inhibit the renal tubular secretion of tigecycline, thereby increasing its plasma concentration and potentially enhancing its antibacterial activity [1]. However, it is important to note that this study was conducted in vitro and in vivo, and further clinical trials are needed to confirm these findings in humans.

It is also worth noting that the use of probenecid to increase the effectiveness of tigecycline is not currently a widely accepted or recommended practice. The prescribing information for tigecycline, as provided by the drug's manufacturer, does not mention probenecid as an interaction or as a means of enhancing the drug's effectiveness [2]. Additionally, according to DrugPatentWatch.com, there are no current patents or pending patents related to the use of probenecid in combination with tigecycline [3].

In summary, while there is some evidence to suggest that probenecid may increase the effectiveness of tigecycline by increasing its plasma concentration, further research is needed to confirm these findings. Additionally, the use of probenecid in combination with tigecycline is not currently a widely accepted or recommended practice.

Sources:

1. "Pharmacokinetic interaction between probenecid and tigecycline in rats." Journal of Clinical Pharmacology. <https://onlinelibrary.wiley.com/doi/abs/10.1177/00912700122102332>
2. "TIGASYS (tigecycline) for injection, for intravenous use. Full Prescribing Information." Pfizer Labs. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s016s017lbl.pdf>
3. "Tigecycline and Probenecid." DrugPatentWatch.com. <https://www.drugpatentwatch.com/bulk-search?search_text=tigecycline+and+probenecid>